Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diffusing capacity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Diffusing capacity. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-020688-18 Sponsor Protocol Number: CQAX576A2203 Start Date*: 2011-06-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in pa...
    Medical condition: Patients with rapidly progressive idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004088-77 Sponsor Protocol Number: BA2006/03/03 Start Date*: 2007-12-03
    Sponsor Name:BioAlliance Pharma
    Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
    Medical condition: Advanced hepatocarcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005678-61 Sponsor Protocol Number: ESNOD-01 Start Date*: 2006-02-22
    Sponsor Name:University Hospital Tuebingen
    Full Title: Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden (Development of a new method for steady-sta...
    Medical condition: Lung function testing (NO- and CO Transferfactor) in healthy subjects
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003010-12 Sponsor Protocol Number: APHP180600 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: «Efficacy of Fluticasone Propionate associated with Salmeterol using inhalation chamber versus placebo to improve the respiratory function in children over six years of age who underwent allogeneic...
    Medical condition: Bronchiolitis Obliterative Syndrome after hematopoietic stem cell transplantation (HSCT). .
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004334-13 Sponsor Protocol Number: MSI-1995-203 Start Date*: 2005-04-08
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001008-23 Sponsor Protocol Number: RIOP-1 Start Date*: 2014-09-26
    Sponsor Name:The Newcastle Upon Tyne Hospital NHS Foundation Trust, Freeman Hospital
    Full Title: Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study
    Medical condition: Pulmonary hypertension WHO Group III (Pulmonary hypertension owing to lung disease and/or hypoxia): Chronic obstructive pulmonary disease(COPD); Pulmonary Fibrosis (PF).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002324-15 Sponsor Protocol Number: P01092 Start Date*: 2007-09-04
    Sponsor Name:University of East Anglia
    Full Title: The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia
    Medical condition: Idiopathic Interstitial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022619 Interstitial pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000041-14 Sponsor Protocol Number: 269050-80-06-19 Start Date*: 2020-06-19
    Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust
    Full Title: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001362-41 Sponsor Protocol Number: ALN-AAT02-001 Start Date*: 2018-12-03
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-...
    Medical condition: ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004937-19 Sponsor Protocol Number: CMHV370A12201 Start Date*: 2021-09-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with ...
    Medical condition: Sjögren’s syndrome Mixed connective tissue disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-001429-30 Sponsor Protocol Number: WA42294 Start Date*: 2021-03-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) DE (Prematurely Ended) SE (Prematurely Ended) GR (Prematurely Ended) HU (Completed) PT (Prematurely Ended) AT (Prematurely Ended) FI (Completed) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000371-26 Sponsor Protocol Number: DFI12712 Start Date*: 2015-08-14
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of olipudase alfa in Patients With...
    Medical condition: Patients with acid sphingomyelinase deficiency (Niemann-Pick Type B disease)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10041515 Sphingomyelin lipidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) PT (Completed) ES (Ongoing) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004058-32 Sponsor Protocol Number: 2014RESP02M(14-01-14) Start Date*: 2014-12-19
    Sponsor Name:Norfolk and Norwich University Hospital NHS Foundation Trust
    Full Title: The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002667-17 Sponsor Protocol Number: CVAY736X2207 Start Date*: 2018-05-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary f...
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended) DE (Completed) IT (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-003801-15 Sponsor Protocol Number: 12011.202 Start Date*: Information not available in EudraCT
    Sponsor Name:PARIPharma GmbH
    Full Title: A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A ...
    Medical condition: Bronchiolitis Obliterans Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049202 Bronchiolitis obliterans LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000791-38 Sponsor Protocol Number: WA42293 Start Date*: 2021-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Completed) DE (Completed) HU (Completed) GR (Prematurely Ended) FI (Completed) PT (Prematurely Ended) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005376-17 Sponsor Protocol Number: 201401 Start Date*: 2014-06-20
    Sponsor Name:Erasmus Medical Center
    Full Title: Sandostatin therapy in sarcoidosis
    Medical condition: Sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006237-42 Sponsor Protocol Number: 39085 Start Date*: 2012-12-12
    Sponsor Name:Erasmus University Rotterdam
    Full Title: Optimization of exercise therapy in type 2 diabetes mellitus
    Medical condition: Insulin resistance, endothelial dysfunction, cardiovascular fitness, cardio-respiratory responses, glycemic control in deconditioned non-insulin dependent type 2 diabetes patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005131-40 Sponsor Protocol Number: MA29957 Start Date*: 2016-10-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATH...
    Medical condition: "Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) BE (Completed) DE (Completed) GR (Completed) HU (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:11:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA